Clinical Trial Update: Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme [Phase 2]

View source ↗

Summary

Phase 2 trial investigating temozolomide with SCH66336 for recurrent glioblastoma multiforme has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme

Drugs mentioned

• SCH66336 (SCH66336)
• Temozolomide (Temozolomide)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Glioblastoma Multiforme | Phase 2 | Status: COMPLETED